Limited value of currently used germline brca mutations predictive tools in prostate cancer

Germline BRCA mutations denote a clinicopathologic subset of prostate cancer.

PURPOSE Increased prostate cancer risk has been reported for BRCA mutation carriers, but BRCA-associated clinicopathologic features have not been clearly defined. EXPERIMENTAL DESIGN We determined BRCA mutation prevalence in 832 Ashkenazi Jewish men diagnosed with localized prostate cancer between 1988 and 2007 and 454 Ashkenazi Jewish controls and compared clinical outcome measures among 26 ...

BRCA mutations in prostate cancer patients.

Effect of BRCA germline mutations on breast cancer prognosis

BACKGROUND The contribution of BRCA germline mutational status to breast cancer patients' prognosis is unclear. We aimed to systematically review and perform meta-analysis of the available evidence of effects of BRCA germline mutations on multiple survival outcomes of breast cancer patients as a whole and in specific subgroups of interest, including those with triple negative breast cancer, tho...

Clinical Management of Prostate Cancer in Men with BRCA Mutations.

This issue of European Urology includes a report on the outcome after local prostate cancer (PCa) treatment in men with mutations in the cancer susceptibility gene breast cancer 1, early onset (BRCA1) or breast cancer 2, early onset (BRCA2) [1]. Germline mutations in these genes confer a much higher risk of breast and ovarian cancers in women and, to a somewhat lesser degree, PCa and other canc...

BRCA mutations and risk of prostate cancer in Ashkenazi Jews.

PURPOSE The Breast Cancer Linkage Consortium and other family-based ascertainments have suggested that male carriers of BRCA mutations are at increased risk of prostate cancer. Several series looking at the frequency of BRCA mutations in unselected patients with prostate cancer have not confirmed this finding. To clarify this issue, we conducted a large case-control study. EXPERIMENTAL DESIGN...